TCM
OBIO icon

Tang Capital Management’s Orchestra BioMed OBIO Stock Holding History

Tang Capital Management’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-392,500
Closed -$3.92M – 117
2022
Q4 		$3.92M Hold
392,500
– – 0.57% 42
2022
Q3 		$3.89M Buy
+392,500
New +$3.89M 0.48% 48

Other funds holding OBIO

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
SFG
SVB Financial Group Dallas, Texas $434K AUM 277.67% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Tang Capital Management's OBIO Position: Q1 2023 in Review

Tang Capital Management sold out of Orchestra BioMed (OBIO) in Q1 2023, closing a stake of 392,500 shares — an estimated $3.92M sold.

Tang Capital Management first reported a position in OBIO in Q3 2022 and held it in 2 quarters. The position peaked at $3.92M in Q4 2022. 22 funds tracked by Wall St. Rank hold OBIO as of Q1 2023.

  • Tang Capital Management reported no remaining Orchestra BioMed position as of Q1 2023 after selling out during the quarter.
  • Tang Capital Management sold 392,500 Orchestra BioMed shares in Q1 2023, an estimated $3.92M.
  • Tang Capital Management first reported a position in Orchestra BioMed in Q3 2022 and held it in 2 quarters.
  • Tang Capital Management's Orchestra BioMed position peaked at $3.92M in Q4 2022.
  • 22 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2023.

Based on Tang Capital Management's 13F filing for Q1 2023, filed 15 May 2023.